A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin, NSC 609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix

Trial Profile

A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin, NSC 609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Jun 2015

At a glance

  • Drugs Topotecan (Primary)
  • Indications Cervical cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Jun 2008 The expected completion date for this trial is now 1 Sep 2006.
    • 08 Jun 2008 Status changed from suspended to in progress, according to ClincalTrials.gov.
    • 06 Nov 2007 Status change from recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top